恶性血液病患者游离Fas的检测及临床意义  

The Serum Levels of Soluble Fas in Patients with Malignant Hematologic Diseases and its Clinical Implication

作　　者：郑佳[1] 刘复强[1] 翟艳玲[1] 刘元波[1] 王天[1] 李守静[1] 赵相印[1] 

机构地区：[1]首都医科大学附属北京同仁医院血液科

出　　处：《首都医科大学学报》2000年第1期43-45,共3页Journal of Capital Medical University

摘　　要：为了解游离Fas (sFas)在恶性血液病中的水平及临床意义 ,用酶联免疫吸附法测定了 6 0例恶性血液病患者的血清sFas。结果 :恶性血液病患者血清sFas质量浓度高于正常人 (P <0 .0 1 ) ,治疗后sFas下降 ,下降的程度与疗效有关 ,但治疗前sFas质量浓度的高低与疗效预测无关。结果提示 :sFas对恶性血液病的诊断及疗效判定有一定意义 ,并可能对其发病机制产生影响。In order to study the serum levels of soluble Fas (sFas) in malignant hematologic diseases and its clinical implication, serum levels of sFas in 60 patients with malignant hematologic diseases and in a control group of 30 health volunteers were measured by sandwich enzyme linked immunosorbent assay (ELISA) method.Before chemotherapy, the serum levels of sFas in patients with malignant hematologic diseases were significantly higher than those of control group( P <0.01), and were not related to respose to chemotherapy. After chemotherapy, the levels of sFas significantly lowered in complete remission (CR) group ( P <0.05), but did not in unremission (NR) group. The levels and changes of sFas might be served as a reference finger to diagnosis some malignant hematologic diseases and to evaluate chemotherapy effect. sFas might be involved in pathogenesis of some malignant hematologic diseases .

关 键 词：游离Fas 恶性血液病 细胞凋亡 

分 类 号：R733[医药卫生—肿瘤]